CDKN2A and neoplasm: Remarkably, loss of Arf resulted in a very significant, nearly 5-fold increase in tumor burden (Figure 2A, p<0.0001); there was, in addition, a 1.8-fold increase in tumor number (Figure 2B, p = 0.002).